AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
“We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors.
- “We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors.
- The positive results from the RUBY trial represent a potential breakthrough for patients with primary advanced or recurrent endometrial cancer,” said Daniel Faga, interim president and chief executive officer of AnaptysBio.
- Jemperli was discovered by AnaptysBio and licensed to TESARO, Inc., now a part of the GSK group of companies, under a Collaboration and Exclusive License Agreement signed in March 2014.
- In 2021, AnaptysBio monetized with Sagard Healthcare Royalty Partners certain commercial milestones and royalties for annual net sales of Jemperli below $1 billion up to a certain amount of receivables before such receivables revert back to AnaptysBio.